Unknown PHASE1 INTERVENTIONAL 1-arm NCT05302843

A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors

A Phase 1，Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ascendind Doses of BPI-28592 in Subjects With Advanced Solid Tumors

Sponsor: Betta Pharmaceuticals Co., Ltd.

Conditions Metastasis, Neoplasm

Interventions BPI-28592

Updated 5 times since 2022 Last updated: Mar 21, 2022 Started: Mar 22, 2021 Primary completion: Dec 31, 2023 Completion: Dec 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Metastasis, Neoplasm, this trial is ongoing. The trial is conducted by Betta Pharmaceuticals Co., Ltd. and has accumulated 5 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE1
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Apr 2024 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Apr 2022 — Apr 2024 [monthly]

Recruiting PHASE1

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Betta Pharmaceuticals Co., Ltd.

Data source: Betta Pharmaceuticals Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China